SCHEMBL6778084

SCHEMBL6778084

NN=CNc1cccc(C(=O)NCC(=O)NC(Cc2ccc(Cl)c(Cl)c2)C(=O)O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 3/20 0.45
FPR2 P25090 1/20 0.44
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
ITGB1 P05556 5/20 0.42
ITGA5 P08648 2/20 0.42
CTSB P07858 2/20 0.41
ITGB3 P05106 3/20 0.40
ITGAV P06756 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ATM Q13315 1/20 0.40
MDM2 Q00987 1/20 0.40
CTSV O60911 1/20 0.40
CTSL P07711 1/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
ITGA2B P08514 2/20 0.39
ITGB5 P18084 2/20 0.39
ITGA4 P13612 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7835253 0.91 ITGB1 (0.42) GPR139CA1CA2ITGB1ITGA5
SCHEMBL6772224 0.91 CTSV (0.50) GPR139CA1CA2ITGB1ITGA5
SCHEMBL3051751 0.90 GPR139 (0.44) GPR139CA1CA2ITGB1ITGA5
SCHEMBL7339157 0.89 TACR1 (0.44) GPR139ITGB1ITGA5CTSBITGB3
SCHEMBL6775970 0.88 GPR132 (0.49) GPR139CA1CA2ITGB1ITGA5
SCHEMBL7823171 0.88 ITGB3 (0.50) ITGB1ITGA5ITGB3ITGAVMDM2
SCHEMBL6779571 0.87 FPR2 (0.43) FPR2ITGB1ITGA5ITGB3ITGAV
SCHEMBL7340124 0.87 CA2 (0.46) GPR139CA2ITGB1ITGA5ITGB3
SCHEMBL7838300 0.87 ITGB3 (0.51) GPR139ITGB1ITGA5CTSBITGB3
SCHEMBL6773776 0.86 CTSB (0.43) FPR2ITGB1ITGA5CTSBITGB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed